BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, Eschenhagen T. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics. 2002;12:465-472. [PMID: 12172215 DOI: 10.1097/00008571-200208000-00007] [Cited by in Crossref: 100] [Cited by in F6Publishing: 85] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Sharp CF, Gardiner SJ, Jensen BP, Roberts RL, Troughton RW, Lainchbury JG, Begg EJ. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. Pharmacogenomics J 2009;9:175-84. [PMID: 19365402 DOI: 10.1038/tpj.2009.9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
2 Chan SW, Hu M, Tomlinson B. The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure. Expert Opinion on Drug Metabolism & Toxicology 2012;8:767-90. [DOI: 10.1517/17425255.2012.685157] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
3 Guo M, Guo G, Ji X. Genetic polymorphisms associated with heart failure: A literature review. J Int Med Res 2016;44:15-29. [PMID: 26769713 DOI: 10.1177/0300060515604755] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
4 Dorn GW 2nd. Pharmacogenetic profiling in the treatment of heart disease. Transl Res 2009;154:295-302. [PMID: 19931195 DOI: 10.1016/j.trsl.2009.07.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
5 Shin J, Hills NK, Finley PR. Combining Antidepressants with β-Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction. Pharmacotherapy 2020;40:507-16. [PMID: 32342526 DOI: 10.1002/phar.2406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kindermann M, Maack C, Schaller S, Finkler N, Schmidt KI, Läer S, Wuttke H, Schäfers HJ, Böhm M. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 2004;109:3182-90. [PMID: 15184276 DOI: 10.1161/01.CIR.0000130849.08704.24] [Cited by in Crossref: 42] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
7 Voora D, Ginsburg GS. Clinical Application of Cardiovascular Pharmacogenetics. Journal of the American College of Cardiology 2012;60:9-20. [DOI: 10.1016/j.jacc.2012.01.067] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
8 Schaeffeler E, Schwab M, Eichelbaum M, Zanger UM. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-rime PCR. Hum Mutat 2003;22:476-85. [DOI: 10.1002/humu.10280] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 6.3] [Reference Citation Analysis]
9 Rasmussen JO, Christensen M, Svendsen JM, Skausig O, Hansen EL, Nielsen KA. CYP2D6 gene test in psychiatric patients and healthy volunteers. Scandinavian Journal of Clinical and Laboratory Investigation 2009;66:129-36. [DOI: 10.1080/00365510500469702] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
10 Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2005;2:475-83. [PMID: 16265588 DOI: 10.1038/ncpcardio0309] [Cited by in Crossref: 89] [Cited by in F6Publishing: 74] [Article Influence: 5.6] [Reference Citation Analysis]
11 Aspromonte N, Monitillo F, Puzzovivo A, Valle R, Caldarola P, Iacoviello M. Modulation of cardiac cytochrome P450 in patients with heart failure. Expert Opinion on Drug Metabolism & Toxicology 2014;10:327-39. [DOI: 10.1517/17425255.2014.872240] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
12 Kertai MD, Esper SA, Akushevich I, Voora D, Ginsburg GS, Stafford-Smith M, Grichnik K, Newman MF, Fontes ML, Smith P, Podgoreanu MV, Mathew JP; Cardiothoracic Anesthesia Research Endeavors (CARE) Group. Preoperative CYP2D6 metabolism-dependent β-blocker use and mortality after coronary artery bypass grafting surgery. J Thorac Cardiovasc Surg 2014;147:1368-1375.e3. [PMID: 24269121 DOI: 10.1016/j.jtcvs.2013.09.067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
13 Cascorbi I, Bruhn O, Werk AN. Challenges in pharmacogenetics. Eur J Clin Pharmacol 2013;69:17-23. [DOI: 10.1007/s00228-013-1492-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
14 Burrello J, Monticone S, Buffolo F, Tetti M, Veglio F, Williams TA, Mulatero P. Is There a Role for Genomics in the Management of Hypertension? Int J Mol Sci 2017;18:E1131. [PMID: 28587112 DOI: 10.3390/ijms18061131] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
15 Kronenberg S, Apter A, Brent D, Schirman S, Melhem N, Pick N, Gothelf D, Carmel M, Frisch A, Weizman A. Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness and Side Effects in Children with Depression and/or Anxiety Disorders. Journal of Child and Adolescent Psychopharmacology 2007;17:741-50. [DOI: 10.1089/cap.2006.0144] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
16 Onalan O, Cumurcu BE, Bekar L. Complete Atrioventricular Block Associated With Concomitant Use of Metoprolol and Paroxetine. Mayo Clinic Proceedings 2008;83:595-9. [DOI: 10.1016/s0025-6196(11)60736-2] [Cited by in Crossref: 11] [Article Influence: 0.8] [Reference Citation Analysis]
17 De T, Park CS, Perera MA. Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White? Annu Rev Pharmacol Toxicol 2019;59:577-603. [PMID: 30296897 DOI: 10.1146/annurev-pharmtox-010818-021154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
18 Li Q, Wang R, Guo Y, Wen S, Xu L, Wang S. Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers: Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers. Journal of Clinical Pharmacy and Therapeutics 2010;35:239-47. [DOI: 10.1111/j.1365-2710.2009.01102.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
19 von Homeyer P, Schwinn DA. Pharmacogenomics of β-adrenergic receptor physiology and response to β-blockade. Anesth Analg 2011;113:1305-18. [PMID: 21965354 DOI: 10.1213/ANE.0b013e31822b887e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
20 Rüdesheim S, Wojtyniak JG, Selzer D, Hanke N, Mahfoud F, Schwab M, Lehr T. Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. Pharmaceutics 2020;12:E1200. [PMID: 33322314 DOI: 10.3390/pharmaceutics12121200] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Dorn GW 2nd. Adrenergic signaling polymorphisms and their impact on cardiovascular disease. Physiol Rev 2010;90:1013-62. [PMID: 20664078 DOI: 10.1152/physrev.00001.2010] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
22 Zanger UM, Schwab M, Toscano C, Eichelbaum M, Raimundo S. Limited Association of the 2988g>a Single Nucleotide Polymorphism with CYP2D6*41 in Black Subjects: Reply*. Clin Pharmacol Ther 2005;77:230-1. [DOI: 10.1016/j.clpt.2004.09.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
23 Nagele P, Liggett SB. Genetic variation, β-blockers, and perioperative myocardial infarction. Anesthesiology 2011;115:1316-27. [PMID: 21918425 DOI: 10.1097/ALN.0b013e3182315eb2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
24 Thomas CD, Mosley SA, Kim S, Lingineni K, El Rouby N, Langaee TY, Gong Y, Wang D, Schmidt SO, Binkley PF, Estores DS, Feng K, Kim H, Kinjo M, Li Z, Fang L, Chapman AB, Cooper-DeHoff RM, Gums JG, Hamadeh IS, Zhao L, Schmidt S, Frye RF, Johnson JA, Cavallari LH. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores. CPT Pharmacometrics Syst Pharmacol 2020;9:678-85. [PMID: 33067866 DOI: 10.1002/psp4.12563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Bonnet-brilhault F, Broly F, Blanc R, Furet Y, Barthélémy C, Paintaud G. An ADHD 6-year-old Child Ultrarapid Metabolizer for CYP2D6. Journal of Clinical Psychopharmacology 2006;26:442-4. [DOI: 10.1097/01.jcp.0000227352.52288.50] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Yang LQ, Yu WF, Cao YF, Gong B, Chang Q, Yang GS. Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes. World J Gastroenterol 2003; 9(9): 1959-1962 [PMID: 12970884 DOI: 10.3748/wjg.v9.i9.1959] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
27 Nieminen T, Uusitalo H, Mäenpää J, Turjanmaa V, Rane A, Lundgren S, Ropo A, Rontu R, Lehtimäki T, Kähönen M. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol 2005;61:811-9. [PMID: 16315032 DOI: 10.1007/s00228-005-0052-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
28 Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, Mckillop D, Wild MJ. Pharmacokinetic Drug Interactions of Gefitinib with Rifampicin, Itraconazole and Metoprolol: . Clinical Pharmacokinetics 2005;44:1067-81. [DOI: 10.2165/00003088-200544100-00005] [Cited by in Crossref: 105] [Cited by in F6Publishing: 95] [Article Influence: 6.6] [Reference Citation Analysis]
29 Steimer W, Zöpf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004;50:1623-33. [PMID: 15205367 DOI: 10.1373/clinchem.2003.030825] [Cited by in Crossref: 98] [Cited by in F6Publishing: 90] [Article Influence: 5.8] [Reference Citation Analysis]
30 Sidjanin DJ, McCarty CA, Patchett R, Smith E, Wilke RA. Pharmacogenetics of ophthalmic topical beta-blockers. Per Med 2008;5:377-85. [PMID: 19266054 DOI: 10.2217/17410541.5.4.377] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
31 Dadova K, Slaby K, Radvansky J, Matous M, Varekova J, Hodis J, Steffl M, Tufano JJ. Exercise prescription in cardiac patients treated with metoprolol - should the time of day for stress tests and training coincide? Eur J Prev Cardiol 2018;25:1026-7. [PMID: 29676165 DOI: 10.1177/2047487318771776] [Reference Citation Analysis]
32 Parker RB, Soberman JE. Effects of Paroxetine on the Pharmacokinetics and Pharmacodynamics of Immediate-Release and Extended-Release Metoprolol. Pharmacotherapy 2011;31:630-41. [DOI: 10.1592/phco.31.7.630] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
33 Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:23-37. [PMID: 14618296 DOI: 10.1007/s00210-003-0832-2] [Cited by in Crossref: 560] [Cited by in F6Publishing: 495] [Article Influence: 31.1] [Reference Citation Analysis]
34 Hamadeh IS, Langaee TY, Dwivedi R, Garcia S, Burkley BM, Skaar TC, Chapman AB, Gums JG, Turner ST, Gong Y, Cooper-DeHoff RM, Johnson JA. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. Clin Pharmacol Ther 2014;96:175-81. [PMID: 24637943 DOI: 10.1038/clpt.2014.62] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
35 Dunham WC, Weinger MB, Slagle J, Pretorius M, Shah AS, Absi TS, Shotwell MS, Beller M, Thomas E, Vnencak-Jones CL, Freundlich RE, Wanderer JP, Sandberg WS, Kertai MD. CYP2D6 Genotype-guided Metoprolol Therapy in Cardiac Surgery Patients: Rationale and Design of the Pharmacogenetic-guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery (PREEMPTIVE) Pilot Study. J Cardiothorac Vasc Anesth 2020;34:20-8. [PMID: 31606278 DOI: 10.1053/j.jvca.2019.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Wojtczak A, Wojtczak M, Skrętkowicz J. The relationship between plasma concentration of metoprolol and CYP2D6 genotype in patients with ischemic heart disease. Pharmacological Reports 2014;66:511-4. [DOI: 10.1016/j.pharep.2013.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
37 Hendset M, Molden E, Knape M, Hermann M. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype. Ther Drug Monit 2014;36:80-5. [PMID: 24232129 DOI: 10.1097/FTD.0000000000000018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
38 Chan SW, Chu TTW, Ho CS, Kong APS, Tomlinson B, Zeng W. Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients. Front Med (Lausanne) 2021;8:683498. [PMID: 34568359 DOI: 10.3389/fmed.2021.683498] [Reference Citation Analysis]
39 Nielsen KA, Lyders Hansen E, Gille S. Genotyping of the cytochrome P450 2D6 4469 C>T polymorphism using SimpleProbes . Scandinavian Journal of Clinical and Laboratory Investigation 2009;67:280-90. [DOI: 10.1080/00365510601039982] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
40 Weeke P, Roden DM. Applied pharmacogenomics in cardiovascular medicine. Annu Rev Med 2014;65:81-94. [PMID: 24111889 DOI: 10.1146/annurev-med-101712-122545] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
41 Verschuren JJ, Trompet S, Wessels JA, Guchelaar HJ, de Maat MP, Simoons ML, Jukema JW. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J 2012;33:165-75. [PMID: 21804109 DOI: 10.1093/eurheartj/ehr239] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
42 Bijl M, Visser L, van Schaik R, Kors J, Witteman J, Hofman A, Vulto A, van Gelder T, Stricker B. Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in β-Blocker Users. Clin Pharmacol Ther 2008;85:45-50. [DOI: 10.1038/clpt.2008.172] [Cited by in Crossref: 91] [Cited by in F6Publishing: 82] [Article Influence: 7.0] [Reference Citation Analysis]
43 Wu D, Li G, Deng M, Song W, Huang X, Guo X, Wu Z, Wu S, Xu J. Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension. J Int Med Res 2015;43:424-34. [PMID: 25823457 DOI: 10.1177/0300060514563151] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
44 Toscano C, Klein K, Blievernicht J, Schaeffeler E, Saussele T, Raimundo S, Eichelbaum M, Schwab M, Zanger UM. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet Genomics 2006;16:755-66. [PMID: 17001295 DOI: 10.1097/01.fpc.0000230112.96086.e0] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 5.6] [Reference Citation Analysis]
45 Walker L, Yip V, Pirmohamed M. Adverse Drug Reactions. Handbook of Pharmacogenomics and Stratified Medicine. Elsevier; 2014. pp. 405-35. [DOI: 10.1016/b978-0-12-386882-4.00020-7] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
46 Oliveira-Paula GH, Pereira SC, Tanus-Santos JE, Lacchini R. Pharmacogenomics And Hypertension: Current Insights. Pharmgenomics Pers Med 2019;12:341-59. [PMID: 31819590 DOI: 10.2147/PGPM.S230201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
47 Guengerich FP. Human Cytochrome P450 Enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450. Cham: Springer International Publishing; 2015. pp. 523-785. [DOI: 10.1007/978-3-319-12108-6_9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
48 Mugoša S, Djordjević N, Djukanović N, Protić D, Bukumirić Z, Radosavljević I, Bošković A, Todorović Z. Factors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient population. Patient Prefer Adherence 2016;10:1461-9. [PMID: 27536078 DOI: 10.2147/PPA.S108579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
49 Meloche M, Khazaka M, Kassem I, Barhdadi A, Dubé MP, de Denus S. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis. Br J Clin Pharmacol 2020;86:1015-33. [PMID: 32090368 DOI: 10.1111/bcp.14247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
50 Lazar A, Tomalik-scharte D, Fuhr U. Applications of genotyping and phenotyping for clinically-relevant polymorphisms of drug metabolizing enzymes and drug transporters. Drug Monitoring and Clinical Chemistry. Elsevier; 2004. pp. 321-53. [DOI: 10.1016/s1567-7192(04)80014-7] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
51 Kirchheiner J, Schwab M. HETEROGENEITY OF DRUG RESPONSES AND INDIVIDUALIZATION OF THERAPY. Pharmacology and Therapeutics. Elsevier; 2009. pp. 225-38. [DOI: 10.1016/b978-1-4160-3291-5.50020-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
52 Bentzen BH, Grunnet M, Hyveled-Nielsen L, Sundgreen C, Lassen JB, Hansen HH. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring) 2013;21:985-92. [PMID: 23784901 DOI: 10.1002/oby.20122] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
53 Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol 2006;20:273-82. [PMID: 16671962 DOI: 10.1111/j.1472-8206.2006.00408.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 3.7] [Reference Citation Analysis]
54 Eadon MT, Chapman AB. A Physiologic Approach to the Pharmacogenomics of Hypertension. Advances in Chronic Kidney Disease 2016;23:91-105. [DOI: 10.1053/j.ackd.2016.02.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
55 Furman KD, Grimm DR, Mueller T, Holley-Shanks RR, Bertz RJ, Williams LA, Spear BB, Katz DA. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics 2004;14:279-84. [PMID: 15115913 DOI: 10.1097/00008571-200405000-00002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
56 Sabbagh A, Darlu P. Data-Mining Methods as Useful Tools for Predicting Individual Drug Response: Application to <i>CYP2D6</i> Data. Hum Hered 2006;62:119-34. [DOI: 10.1159/000096416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
57 Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. 2007;27:874-887. [PMID: 17542770 DOI: 10.1592/phco.27.6.874] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 6.6] [Reference Citation Analysis]
58 Mörike K, Kivistö K, Schaeffeler E, Jägle C, Igel S, Drescher S, Fux R, Marx C, Hofmann U, Engel C, Wagner F, Delabar U, Meisner C, Bail D, Böhm J, Gleiter C, Ziemer G, Rein J, Hellberg K, Eichelbaum M, Schwab M. Propafenone for the Prevention of Atrial Tachyarrhythmias After Cardiac Surgery: A Randomized, Double-blind Placebo-controlled Trial. Clin Pharmacol Ther 2008;84:104-10. [DOI: 10.1038/sj.clpt.6100473] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
59 Wilke RA, Musana A, Weber WW. Cytochrome P450 gene-based drug prescribing and factors impacting translation into routine clinical practice. Personalized Medicine 2005;2:213-24. [DOI: 10.2217/17410541.2.3.213] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
60 Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol 2008;64:1163-73. [DOI: 10.1007/s00228-008-0525-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
61 Guengerich FP. Human Cytochrome P450 Enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450. Boston: Springer US; 2005. pp. 377-530. [DOI: 10.1007/0-387-27447-2_10] [Cited by in Crossref: 176] [Cited by in F6Publishing: 95] [Reference Citation Analysis]
62 Nozawa T, Taguchi M, Tahara K, Hashimoto Y, Igarashi N, Nonomura M, Kato B, Igawa A, Inoue H. Influence of CYP2D6 Genotype on Metoprolol Plasma Concentration and β-Adrenergic Inhibition During Long-Term Treatment: A Comparison With Bisoprolol. Journal of Cardiovascular Pharmacology 2005;46:713-20. [DOI: 10.1097/01.fjc.0000184117.76188.68] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
63 Thuerauf N, Lunkenheimer J. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci 2006;256:287-93. [DOI: 10.1007/s00406-006-0663-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
64 Luzum JA, Sweet KM, Binkley PF, Schmidlen TJ, Jarvis JP, Christman MF, Sadee W, Kitzmiller JP. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure. Pharm Res 2017;34:1615-25. [PMID: 28181117 DOI: 10.1007/s11095-017-2104-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
65 Rollinson V, Turner R, Pirmohamed M. Pharmacogenomics for Primary Care: An Overview. Genes (Basel) 2020;11:E1337. [PMID: 33198260 DOI: 10.3390/genes11111337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
66 Clarke J, Cutler M, Gong I, Schwarz UI, Freeman D, Dasgupta M. Cytochrome P450 2D6 Phenotyping in an Elderly Population With Dementia and Response to Galantamine in Dementia: A Pilot Study. The American Journal of Geriatric Pharmacotherapy 2011;9:224-33. [DOI: 10.1016/j.amjopharm.2011.07.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
67 Baudhuin LM, Miller WL, Train L, Bryant S, Hartman KA, Phelps M, Larock M, Jaffe AS. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Am J Cardiol 2010;106:402-8. [PMID: 20643254 DOI: 10.1016/j.amjcard.2010.03.041] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
68 Hannah-Shmouni F, Seidelmann SB, Sirrs S, Mani A, Jacoby D. The Genetic Challenges and Opportunities in Advanced Heart Failure. Can J Cardiol 2015;31:1338-50. [PMID: 26518444 DOI: 10.1016/j.cjca.2015.07.735] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
69 Jin SK, Chung HJ, Chung MW, Kim J, Kang J, Woo SW, Bang S, Lee SH, Lee HJ, Roh J. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. Journal of Clinical Pharmacy and Therapeutics 2008;33:567-73. [DOI: 10.1111/j.1365-2710.2008.00945.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
70 El-armouche A, Eschenhagen T. β-Adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev 2009;14:225-41. [DOI: 10.1007/s10741-008-9132-8] [Cited by in Crossref: 137] [Cited by in F6Publishing: 124] [Article Influence: 10.5] [Reference Citation Analysis]
71 Cascorbi I. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur J Clin Invest 2003;33 Suppl 2:17-22. [PMID: 14641552 DOI: 10.1046/j.1365-2362.33.s2.3.x] [Cited by in Crossref: 148] [Cited by in F6Publishing: 125] [Article Influence: 8.7] [Reference Citation Analysis]
72 Tieu A, Velenosi TJ, Kucey AS, Weir MA, Urquhart BL. β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. Clin J Am Soc Nephrol 2018;13:604-11. [PMID: 29519953 DOI: 10.2215/CJN.07470717] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
73 Onalan O, Cumurcu BE, Bekar L. Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. Mayo Clin Proc 2008;83:595-9. [PMID: 18452693 DOI: 10.4065/83.5.595] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
74 Eschenhagen T, Blankenberg S. [Personalized therapy in cardiology. Biomarkers, pharmacogenetics and therapy of monogenic diseases]. Internist (Berl) 2013;54:147-8, 150-2, 154. [PMID: 23371262 DOI: 10.1007/s00108-012-3157-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
75 Rau T, Wuttke H, Michels L, Werner U, Bergmann K, Kreft M, Fromm M, Eschenhagen T. Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol: A Prospective Longitudinal Study. Clin Pharmacol Ther 2008;85:269-72. [DOI: 10.1038/clpt.2008.218] [Cited by in Crossref: 88] [Cited by in F6Publishing: 71] [Article Influence: 6.8] [Reference Citation Analysis]
76 Ma JD, Nafziger AN, Bertino JS. Genetic Polymorphisms of Cytochrome P450 Enzymes and the Effect on Interindividual, Pharmacokinetic Variability in Extensive Metabolizers. The Journal of Clinical Pharmacology 2004;44:447-56. [DOI: 10.1177/0091270004264642] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
77 Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 2008;64:275-82. [PMID: 18043911 DOI: 10.1007/s00228-007-0404-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
78 Feng Y, Pollock BG, Ferrell RE, Kimak MA, Reynolds CF 3rd, Bies RR. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol 2006;61:558-69. [PMID: 16669849 DOI: 10.1111/j.1365-2125.2006.02629.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
79 Jaquenoud Sirot E, Willem van der Velden J, Rentsch K, Eap CB, Baumann P. Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance: . Drug Safety 2006;29:735-68. [DOI: 10.2165/00002018-200629090-00001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
80 Barclay ML, Sawyers SM, Begg EJ, Zhang M, Roberts RL, Kennedy MA, Elliott JM. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status: . Pharmacogenetics 2003;13:627-32. [DOI: 10.1097/00008571-200310000-00006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
81 Wells QS, Delaney JT, Roden DM. Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol 2012;27:253-61. [PMID: 22382501 DOI: 10.1097/HCO.0b013e32835220e3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
82 Jhun EH, Apfelbaum JL, Dickerson DM, Shahul S, Knoebel R, Danahey K, Ratain MJ, O'Donnell PH. Pharmacogenomic considerations for medications in the perioperative setting. Pharmacogenomics 2019;20:813-27. [PMID: 31411557 DOI: 10.2217/pgs-2019-0040] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
83 Bernard PS, Wooderchak-Donahue W, Wei M, Bray SM, Wood KC, Parikh B, McMillin GA. Potential Utility of Pre-Emptive Germline Pharmacogenetics in Breast Cancer. Cancers (Basel) 2021;13:1219. [PMID: 33799547 DOI: 10.3390/cancers13061219] [Reference Citation Analysis]
84 Yin S, Ni Y, Wang S, Wang X, Lou Y, Zhang G. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations: Genetic variant of CYP2C19 and CYP2D6 in Chinese Mongolian, Hui and Han. Journal of Clinical Pharmacy and Therapeutics 2012;37:364-9. [DOI: 10.1111/j.1365-2710.2011.01298.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
85 Batty JA, Hall AS, White HL, Wikstrand J, de Boer RA, van Veldhuisen DJ, van der Harst P, Waagstein F, Hjalmarson Å, Kjekshus J, Balmforth AJ. An Investigation of CYP2D6 Genotype and Response to Metoprolol CR/XL During Dose Titration in Patients With Heart Failure: A MERIT-HF Substudy. Clin Pharmacol Ther 2013;95:321-30. [DOI: 10.1038/clpt.2013.193] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]